Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports Third Quarter Financial Results and Business HighlightsNovember 12, 2021

Emmaus Life Sciences, Inc. today reported financial results for the quarter and nine months ended September 30, 2021.

Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease PatientsNovember 11, 2021

Emmaus Life Sciences, Inc. today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.

Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support ServicesNovember 04, 2021

Emmaus Life Sciences, Inc. today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari.

Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for EndariOctober 26, 2021

Emmaus Life Sciences today announced the submission of its application for marketing authorization of Endari® to the United Arab Emirates (U.A.E.) Ministry of Health.

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos MedicineOctober 12, 2021

Agreement Expands on the Companies’ Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies